University Hospital Zurich at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

University Hospital Zurich brings 2 presentations to ESGCT 2026 in Hamburg. Its work at the meeting centres on making CAR T cells work harder against cancer. One line targets LILRB2 to improve CAR T activity in acute myeloid leukaemia, another delivers interleukin-2 only inside the tumour to help CAR T cells in solid tumours.

OrganizationESGCT 2026 Attendance
University Hospital Zurich
Zurich, Switzerland
usz.ch
Hospitals & clinical centres
University hospital in Zurich, Switzerland.
Talk
Tue Oct 27
6:15pm–7:30pm
LILRB2 targeting enhances CAR T cell efficacy in acute myeloid leukemia
SESSION 2c: Immunotherapy and CAR T cells I
Cell therapies and CAR-TCancer gene and cell therapy
Poster
Wed Oct 28
1:30pm–3:30pm
Tumor-Restricted IL-2 Delivery Enhances CAR T-Cell Efficacy Against Solid Tumors
Immunotherapy and CAR T cells

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from University Hospital Zurich

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction